indol
repres
one
import
privileg
scaffold
drug
discoveri
indol
deriv
uniqu
properti
mimick
structur
peptid
bind
revers
enzym
provid
tremend
opportun
discov
novel
drug
differ
mode
action
seven
indolecontain
commerci
drug
best
sell
drug
us
retail
sale
also
amaz
number
approv
indolecontain
drug
market
well
compound
current
go
differ
clinic
phase
registr
status
review
focus
recent
develop
indol
deriv
antivir
agent
follow
object
present
one
comprehens
list
indol
antivir
agent
drug
market
compound
clinic
trial
focu
recent
develop
indol
compound
includ
natur
product
antivir
activ
summar
structur
properti
hope
inspir
new
even
creativ
approach
offer
perspect
indol
scaffold
privileg
structur
might
exploit
futur
indol
deriv
occur
wide
natur
product
exist
differ
kind
plant
anim
marin
organ
indol
core
nearubiquit
compon
biolog
activ
natur
product
exampl
acid
iaa
fig
one
common
naturallyoccur
plant
hormon
auxin
class
tryptophan
essenti
amino
acid
particip
mani
essenti
biolog
process
serotonin
biochem
deriv
tryptophan
neurotransmitt
found
bilater
anim
melatonin
hormon
found
anim
plant
microb
anim
use
variat
durat
melatonin
product
day
season
clock
indol
core
also
well
known
one
import
scaffold
drug
discoveri
major
focu
research
gener
biolog
studi
diindolylmethan
dim
also
natur
product
deriv
digest
found
rel
high
level
crucifer
veget
broccoli
brussel
sprout
cabbag
kale
subject
ongo
research
due
interest
anticarcinogen
antioxid
antiatherogen
effect
ajmalicin
also
known
dyohimbin
raubasin
indol
alkaloid
found
natur
variou
plant
antihypertens
drug
use
treatment
high
blood
pressur
act
adrenerg
receptor
antagonist
preferenti
action
adrenerg
receptor
underli
hypotens
rather
hypertens
effect
reserpin
indol
alkaloid
use
treat
high
blood
pressur
sever
agit
patient
mental
disord
vinblastin
use
treat
sever
type
cancer
includ
hodgkin
diseas
kaposi
sarcoma
nonhodgkin
lymphoma
cancer
breast
testicl
indol
repres
one
import
structur
motif
drug
discoveri
describ
one
privileg
scaffold
term
first
introduc
evan
cowork
defin
scaffold
capabl
serv
ligand
divers
array
receptor
indol
deriv
uniqu
properti
mimick
structur
peptid
bind
revers
enzym
provid
tremend
opportun
discov
novel
drug
differ
mode
action
seven
indolecontain
commerci
drug
best
sell
drug
us
retail
sale
highlight
ciali
approv
drug
treatment
men
erectil
dysfunct
ed
sign
symptom
benign
prostat
hyperplasia
bph
ed
sign
symptom
bph
also
amaz
number
approv
indolecontain
drug
market
well
compound
current
go
differ
clinic
phase
registr
status
viral
diseas
extrem
widespread
infect
familiar
viral
diseas
includ
common
cold
influenza
chickenpox
herp
gastroenter
stomach
flu
human
immunodefici
viru
hivaid
hepat
viral
diseas
lead
seriou
potenti
lifethreaten
complic
estim
viral
infect
respons
ill
occur
develop
countri
sever
acut
respiratori
syndrom
sar
epidem
origin
southern
china
owe
vast
number
indolecontain
molecul
literatur
review
focus
primarili
antivir
agent
limit
report
found
area
review
serv
comprehens
overview
current
publish
indol
antivir
agent
follow
object
present
one
comprehens
list
indol
antivir
agent
drug
market
compound
clinic
trial
focu
recent
develop
indol
compound
includ
natur
product
antivir
activ
summar
structur
properti
hope
inspir
new
even
creativ
approach
offer
perspect
indol
scaffold
privileg
structur
might
exploit
futur
indol
scaffold
wide
use
antivir
research
exampl
market
indolecontain
antivir
drug
includ
arbidol
delavirdin
meanwhil
number
indol
deriv
activ
undergo
differ
phase
clinic
evalu
atevirdin
golotimod
panobinostat
bilb
enfuvirtid
fig
arbidol
umifenovir
fig
repres
one
highli
function
indolecontain
drug
arbidol
russian
develop
broad
spectrum
antivir
wide
use
russia
china
sinc
use
treatment
prophylact
prevent
influenza
b
viru
respiratori
syncyti
viru
sar
arbidol
demonstr
immunomodul
antiinfluenza
effect
specif
influenza
group
b
sar
prevent
contact
entri
viru
cell
inhibit
fusion
viral
lipid
membran
cell
membran
interferoninduc
action
stimul
humor
cellmedi
immun
help
phagocyt
action
macrophag
heighten
bodi
abil
fight
infect
decreas
frequenc
complic
associ
viral
infect
lessen
effect
chronic
bacteri
ill
addit
arbidol
also
show
vitro
vivo
activ
panel
human
respiratori
virus
includ
influenza
viru
flua
respiratori
syncyti
viru
rsv
human
rhinoviru
hrv
coxsacki
viru
adenoviru
type
hcv
delavirdin
rescriptor
fig
first
gener
nonnucleosid
revers
transcriptas
inhibitor
nnrti
market
viiv
healthcar
approv
fda
treatment
fig
structur
indolecontain
commerci
onstudi
antivir
drug
human
immunodefici
viru
type
use
part
highli
activ
antiretrovir
therapi
haart
sinc
better
nnrti
efavirenz
second
gener
nnrti
etravirin
rilpivirin
approv
http
aidsinfo
delavirdin
inhibit
metabol
hiv
proteas
inhibitor
therebi
increas
system
exposur
proteas
inhibitor
abil
delavirdin
enhanc
pharmacokinet
profil
proteas
inhibitor
may
permit
use
simplifi
administr
regimen
atevirdin
fig
new
nonnucleosid
heteroarylpiperazin
revers
transcriptas
inhibitor
studi
treatment
hiv
atevirdin
mesyl
shown
signific
antihiv
rt
activ
vitro
inhibit
replic
infect
peripher
blood
leukocyt
cultur
inhibitori
concentr
nm
concentr
cytotox
cell
mm
also
inhibit
complet
format
syncytia
human
tcell
leukemia
viru
type
iiiinfect
cell
mm
phase
studi
atevirdin
alon
fail
demonstr
signific
antiretrovir
activ
fosdevirin
fdv
formerli
fig
novel
potent
select
oncedaili
od
nextgener
nonnucleosid
reversetranscriptas
inhibitor
nnrti
low
nanomolar
activ
vitro
show
good
activ
broad
rang
strain
includ
efavirenzresist
efvr
clinic
isol
mg
od
day
well
toler
demonstr
potent
antivir
activ
treatmentna
hivinfect
subject
favor
pk
resist
profil
develop
place
clinic
hold
us
food
drug
administr
pend
evalu
report
seizur
studi
treatmentexperienc
patient
golotimod
fig
oral
bioavail
synthet
peptid
contain
amino
acid
dglutamin
ltryptophan
connect
gammaglutamyl
linkag
potenti
immunostimul
antimicrobi
antineoplast
activ
sciclon
pharmaceut
inc
report
result
phase
clinic
trial
treatment
hepat
c
hcv
studi
evalu
safeti
immunomodulatori
effect
monotherapi
combin
ribavirin
relaps
hcv
patient
clinic
data
demonstr
safe
welltoler
administ
dose
result
show
clear
biolog
signal
meet
studi
primari
efficaci
endpoint
log
reduct
viral
load
baselin
level
phase
studi
still
ongo
attenu
oral
mucos
subject
head
neck
cancer
howev
studi
list
hcv
panobinostat
fig
experiment
drug
develop
novarti
nonselect
histon
deacetylas
inhibitor
hdac
inhibitor
treatment
multipl
myeloma
phase
iii
acut
myeloid
leukemia
phase
ii
variou
hdac
inhibitor
display
signific
potenc
differ
stimul
express
latent
infect
cell
line
panobinostat
significantli
potent
hdac
inhibitor
induc
viru
product
even
low
concentr
rang
nm
proof
obtain
panobinostat
induc
viru
product
latent
infect
primari
cell
therapeut
concentr
current
use
phase
iii
clinic
trial
aim
cure
aid
patient
highli
activ
antiretrovir
therapi
haart
techniqu
panobinostat
use
drive
hiv
dna
patient
dna
expect
patient
immun
system
combin
haart
destroy
first
proof
viral
kick
lead
consist
plasma
releas
viral
particl
fig
first
thumb
pocket
inhibitor
demonstr
antivir
activ
patient
chronic
infect
genotyp
hcv
base
discoveri
alloster
thumb
pocket
nonnucleosid
inhibitor
hcv
polymeras
inhibit
replic
replicon
system
identif
metabol
liabil
common
mani
previous
report
inhibitor
seri
spars
matrix
indolebas
inhibitor
gener
provid
collect
inhibitor
satisfi
potenc
criteria
display
improv
vitro
adm
profil
compound
provid
optim
balanc
antivir
potenc
consist
crossspeci
pk
profil
select
develop
follow
clinic
studi
hcvinfect
patient
fig
cyclopropylfus
indolobenzazepin
hcv
rnadepend
polymeras
inhibitor
inhibit
cellar
replic
hcv
subgenom
replicon
repres
genotyp
ec
nm
nm
respect
also
exhibit
notabl
enhanc
pharmacokinet
profil
improv
solubl
membran
permeabl
found
perform
distinguish
antivir
safeti
pharmacokinet
properti
result
select
clinic
evalu
phase
iii
studi
current
ongo
fig
tetracycl
indolebas
inhibitor
current
phase
clinic
trial
part
allor
interferonfre
regimen
treatment
hcv
infect
protein
play
critic
role
replic
hcv
inhibitor
shown
impress
vitro
potenc
profil
hcv
replicon
assay
make
inhibitor
attract
compon
inclus
oral
combin
regimen
second
gener
inhibitor
combin
proteas
inhibitor
candid
drug
exhibit
improv
genet
barrier
maintain
potenc
yield
amaz
result
term
efficaci
toler
safeti
phase
ii
clinic
trial
underway
interim
analysi
noncirrhot
patient
administ
regimen
without
ribavirin
rbv
sustain
viral
respons
svr
observ
percent
patient
administ
alon
percent
administ
plu
rbv
kind
interferonfre
therapi
expect
lead
hcv
treatment
high
cost
overcom
enfuvirtid
brand
name
fuzeon
fig
peptid
antihiv
drug
target
heptad
repeat
nhr
approv
us
fda
first
hiv
fusionentri
inhibitor
treatment
hivaid
patient
fail
respond
current
antiretrovir
drug
howev
lack
pocketbind
domain
exhibit
low
activ
short
halflif
fig
nonzwitterion
macrocycl
indol
yield
potent
select
fingerloop
inhibitor
hepat
c
viru
hcv
polymeras
lead
optim
conjunct
vivo
evalu
rat
identifi
compound
show
nanomolar
potenc
ec
nm
hcv
replicon
cell
limit
toxic
offetarget
activ
encourag
preclin
pharmacokinet
profil
character
high
liver
distribut
current
evalu
phase
ii
clinic
trial
combin
simeprevir
gener
idea
modern
antivir
drug
design
identifi
viral
protein
part
protein
disabl
gener
speak
target
unlik
protein
part
protein
human
possibl
reduc
likelihood
side
effect
target
also
common
across
mani
strain
viru
even
among
differ
speci
viru
famili
mean
singl
drug
broad
effect
target
identifi
candid
drug
select
either
drug
alreadi
known
appropri
effect
actual
design
candid
molecular
level
computeraid
design
program
mention
introduct
arbidol
act
inhibitor
viru
entri
membran
fusion
broadspectrum
antivir
agent
inhibit
acut
chronic
hcv
infect
use
arbidol
lead
compound
grazia
sellitto
cowork
report
synthesi
evalu
seri
ethyl
deriv
fig
compound
exhibit
strong
antihcv
effect
compound
show
higher
select
indic
inhibit
entri
replic
synthet
initi
hit
compound
potent
candid
reveal
elimin
phenylsulfonyl
moieti
preserv
antihcv
activ
remov
group
indol
ring
arbidol
influenc
antihcv
efficaci
impli
indol
core
rather
group
might
antivir
pharmacophor
report
prototyp
novel
hiv
attach
inhibitor
block
interact
first
step
entri
cell
fig
initi
screen
hit
indol
analog
interfer
interact
hiv
surfac
protein
host
cell
receptor
deriv
exhibit
markedli
enhanc
potenc
bioavail
rat
dog
cynomolgu
monkey
administ
oral
solut
formul
howev
aqueou
suspens
poorli
bioavail
indic
dissolutionlimit
absorpt
deriv
exhibit
improv
pharmaceut
properti
retain
inhibitori
profil
compound
seung
joo
cho
cowork
employ
silico
method
molecular
dock
md
simul
threedimension
quantit
structureact
relationship
guid
molecular
design
new
indol
deriv
fig
data
set
indolebas
inhibitor
along
biolog
activ
collect
literatur
approach
lowest
energi
conform
potent
compound
deriv
systemat
conform
search
consid
templat
sketch
rest
molecul
studi
also
contribut
better
understand
bind
pose
inhibitor
glycoprotein
provid
structur
inform
affect
activ
inhibitor
improv
understand
ligandereceptor
interact
result
use
ration
suggest
design
novel
inhibitor
hivaid
therapi
viruscel
fusion
primari
mean
human
immunodefici
hiv
deliv
genet
materi
human
tcell
host
fusion
mediat
larg
part
viral
glycoprotein
hydrophob
pocket
ntermin
heptad
repeat
nhr
domain
play
import
role
viral
fusion
entri
host
cell
serv
attract
target
develop
fusionentri
inhibitor
robert
c
rizzo
cowork
review
current
approach
studi
interact
inhibitor
put
emphasi
atomiclevel
comput
model
method
fig
compound
antifus
activ
report
interact
specif
manner
bind
site
form
conserv
residu
exampl
compound
discov
virtual
screen
fusion
inhibitor
target
high
geometr
overlap
carboxyl
acid
long
hydrophob
interfac
show
submicromolar
bind
fusion
inhibit
block
viral
replic
molecular
simul
show
abl
adopt
structur
mimick
hydrophob
contact
dpeptid
exhibit
effect
activ
envmedi
cellecel
fusion
ic
valu
mm
bound
hydrophob
pocket
make
favor
interact
reversetranscriptas
inhibitor
rti
class
antiretrovir
drug
use
treat
hiv
infect
aid
case
hepat
b
rti
inhibit
activ
revers
transcriptas
viral
dna
polymeras
requir
replic
hiv
retrovirus
summar
recent
progress
discoveri
design
indol
deriv
rti
compound
fig
indolylarylsulfon
ia
deriv
endow
high
select
potenc
wt
mutant
develop
merck
novel
inhibitor
hiv
revers
transcriptas
use
prevent
treatment
hiv
infect
aid
follow
develop
indolylarylsulfon
iass
nnrti
base
refer
compound
mainli
four
structur
modif
site
includ
benzen
group
ph
sulfonyl
amid
substitu
indol
ring
romano
silvestri
et
al
report
seri
indolylarylsulfon
deriv
fig
analogu
compound
obtain
introduc
two
methyl
group
posit
benzenesulfonyl
moieti
coupl
glycinamidealaninamid
unit
carboxyamid
function
cellbas
assay
show
compound
exhibit
higher
potenc
wild
type
nnrtiresist
mutant
parent
indol
deriv
base
previou
work
giusepp
la
regina
cowork
synthes
seri
novel
ia
deriv
bear
nitrogencontain
substitu
link
ch
ch
ch
spacer
fig
iass
prove
potent
inhibitor
wt
strain
cell
low
nanomolar
concentr
weakli
cytotox
sever
compound
also
identifi
potent
inhibitor
mutant
strain
zhijian
zhao
cowork
merck
report
design
synthesi
biolog
evalu
novel
sulfonamid
potent
nnrti
balanc
profil
common
hiv
rt
mutant
fig
introduct
pyrrolidin
sulfonamid
indol
ring
lead
compound
led
analog
excel
wildtyp
hiv
rt
potenc
compar
weak
rt
activ
compound
variat
indol
show
improv
activ
wildtyp
mutant
rino
ragno
cowork
perform
dock
simul
design
synthes
seri
novel
deriv
n
carboxamid
substitut
n
carboxyhydrazid
deriv
show
high
activ
rt
mutant
viru
fig
meanwhil
deriv
deriv
turn
potent
inhibitor
wt
nnrtiresist
rt
rt
strain
particular
compound
except
potent
rt
wt
rt
carri
mutat
new
indolylarylsulfon
deriv
bear
cyclic
substitu
link
methylen
recent
seri
new
indolylarylsulfon
nnrti
synthes
evalu
unexplor
substitut
benzylphenylethyl
group
link
fig
compound
exhibit
higher
antivir
activ
wt
strain
refer
nvp
efv
azt
respect
addit
sever
compound
show
nanomolar
potenc
toward
mutant
strain
superior
efv
deriv
superior
efv
mutant
strain
interestingli
enantiom
show
small
differ
activ
strain
turn
significantli
potent
whole
panel
mutant
strain
enzymat
result
well
agreement
cellular
data
molecular
simul
suggest
differ
observ
inhibitori
activ
two
isom
could
due
kinet
rather
affin
differ
result
show
compound
repres
robust
lead
compound
develop
nnrti
improv
activ
select
frequent
emerg
mutat
efvtreat
patient
idenix
pharmaceut
merck
co
show
renew
interest
iass
replac
group
either
arylphosphonyl
sulfonamid
group
francesco
piscitelli
report
new
potent
indolylarylsulfon
ia
nnrti
obtain
coupl
natur
unnatur
amino
acid
introduc
differ
electronwithdraw
substitu
posit
andor
indol
ring
fig
new
iass
inhibit
replic
human
tlymphocyt
cem
cell
lowsubnanomolar
concentr
weakli
cytostat
francoisren
alexandr
cowork
design
synthes
seri
indol
novel
nnrti
fig
substitut
bicycl
hydrogen
donor
scaffold
could
interact
branch
phosphoru
tetrahedr
linker
would
direct
substitut
toward
lipophil
region
chemic
variat
phosphoru
linker
led
discoveri
show
excel
potenc
wildtyp
singl
mutant
revers
transcriptas
gene
importantli
addit
potenc
pharmacokinet
solubl
metabol
properti
seri
compound
also
encourag
util
molecular
model
mohammad
hassam
cowork
design
synthes
seri
novel
cyclopropyl
indol
deriv
hiv
nonnucleosid
revers
transcriptas
inhibitor
inhibitor
facilit
doubl
hydrogen
bond
interact
effici
occupi
hydrophob
pocket
region
sever
compound
fig
inhibit
hiv
replic
effect
nevirapin
test
phenotyp
assay
rilpivirin
recent
fdaapprov
nnrti
uncommon
structur
featur
cyanovinyl
cv
group
medicin
chemist
view
substructur
concern
aris
cv
group
may
suffici
electrophil
act
michael
acceptor
lead
potenti
coval
modif
protein
nucleic
acid
biolog
entiti
although
realiti
unsatur
nitril
poor
michael
acceptor
requir
reactiv
organometal
nucleophil
undergo
conjug
addit
fact
almost
approv
drug
contain
cyanovinyl
group
lack
preced
often
taken
warn
sign
drug
discoveri
keep
consider
mind
wongil
lee
cowork
carri
comput
simul
guid
molecular
design
bicycl
replac
cvp
group
led
discoveri
compound
fig
wildtyp
viru
three
compound
exhibit
ec
valu
nm
nm
nm
respect
unfortun
compound
show
promis
potenc
toward
mutant
strain
includ
challeng
variant
contain
doubl
mutat
rt
enzym
haib
zhou
cowork
describ
design
synthesi
biolog
evalu
indolebas
trifluoropropano
effici
inhibitor
revers
transcriptas
rt
fig
inhibitori
activ
two
enantiom
correspond
racem
mixtur
compar
among
nonracem
racem
compound
enantiom
rconfigur
usual
show
lowest
ec
valu
exampl
risom
compound
identifi
activ
candid
test
tzmbl
cell
hiv
viru
type
ec
valu
nm
cc
valu
mm
si
select
index
cc
ec
valu
respect
base
butterflyshap
wing
pharmacophor
requir
ashok
penta
cowork
design
novel
acid
analog
nnrti
molecular
model
lipinski
rule
five
paramet
toxic
paramet
design
analog
employ
predict
ration
structur
fig
among
design
analog
show
signific
bind
free
energi
predict
inhibitori
constant
valu
screen
next
level
studi
predict
poor
pharmacokinet
toxic
profil
current
treatment
hivaid
employ
combin
therapeut
agent
target
viral
revers
transcriptas
proteas
enzym
viral
entri
howev
abil
hiv
rapidli
evolv
resist
agent
togeth
signific
side
effect
requir
develop
new
antivir
drug
novel
mode
action
therefor
urgent
task
develop
novel
agent
interfer
altern
stage
viral
life
cycl
integras
catalyz
integr
hiv
genom
cellular
chromosom
essenti
process
hiv
replic
mammalian
counterpart
integras
becom
attract
target
antivir
drug
design
furthermor
integras
use
singl
activ
site
accommod
two
differ
configur
dna
substrat
may
constrain
abil
hiv
develop
drug
resist
integras
inhibitor
ini
discoveri
new
ini
attract
great
interest
medicin
chemist
recent
year
hui
xu
cowork
design
synthes
eight
simpl
narylindol
integras
inhibitor
vitro
first
time
fig
among
structur
simpl
compound
compound
exhibit
highest
potenc
integras
ec
valu
mgml
ti
valu
diketo
acid
dka
deriv
independ
discov
scientist
shionogi
merck
new
class
integras
inhibitor
fig
order
establish
coher
structureact
relationship
among
substitut
indol
nucleu
bear
bdiketo
acid
moieti
mario
sechi
cowork
design
seri
substitut
indolebas
dka
deriv
show
antiin
activ
low
micromolar
concentr
vari
select
strand
transfer
process
experiment
result
demonstr
diketo
acid
function
import
select
strand
transfer
aromat
ring
play
major
role
potenc
howev
select
strand
transfer
suffici
antivir
activ
although
diketo
acidcontain
compound
repres
novel
class
compound
consid
step
forward
drug
design
target
mani
analogu
show
signific
cytotox
lack
antivir
activ
work
demonstr
physicochem
properti
compound
could
potenti
make
major
contribut
antivir
activ
vitro
subsequ
order
investig
influenc
diketo
acid
moieti
biolog
activ
cytotox
stefania
ferro
cowork
design
synthes
seri
novel
compound
correspond
analogu
carbonyl
one
fig
one
moieti
introduc
suitabl
replac
bdiketo
acid
motif
even
furanon
deriv
gener
exhibit
good
potenc
micromolar
rang
comparison
deriv
correspond
diketo
acid
point
diminish
potenc
enzymat
cell
assay
result
suggest
replac
bdiketo
acid
motif
neg
influenc
vitro
biolog
activ
probabl
due
reduc
conform
mobil
close
system
respect
open
form
apart
target
critic
protein
manipul
specif
proteineprotein
interact
ppi
involv
hiv
life
cycl
could
potenti
result
potent
drug
lack
cellular
toxic
exampl
interact
integras
cellular
protein
len
epitheliumderiv
growth
factor
transcript
coactiv
recent
gain
attent
valuabl
target
novel
antivir
strategi
exampl
chimirri
cowork
establish
structurebas
pharmacophor
model
base
xray
crystal
structur
complex
ibd
pharmacophor
model
use
queri
virtual
screen
approach
filter
librari
small
molecul
produc
compound
best
hit
optim
compound
fig
obtain
agreement
predict
compound
show
higher
potenc
compound
prove
activ
molecul
provid
valid
start
point
discoveri
new
potent
deriv
abl
disrupt
ppi
intracellular
cofactor
number
ration
modif
indol
system
benzyl
moieti
acid
concentr
rang
moreov
magnesium
compound
show
good
antivir
activ
infect
cell
first
data
regard
activ
metal
complex
alloster
inhibitor
offer
promis
approach
prevent
viral
replic
underlin
possibl
use
coordin
chemistri
obtain
unconvent
scaffold
target
enzym
base
previous
obtain
sar
inform
benzylindol
deriv
antihiv
agent
stefania
ferro
cowork
report
research
identif
new
dual
target
small
molecul
abl
target
differ
step
life
cycl
fig
obtain
two
seri
novel
antihiv
agent
dual
inhibitor
integr
process
act
strandtransf
step
disrupt
proteineprotein
interact
cofactor
ledgf
compound
activ
one
laura
de
luca
cowork
use
fragment
hop
approach
design
synthes
novel
nonpeptidyl
compound
fig
mimic
biolog
function
ibd
residu
particular
ledgf
hot
spot
residu
howev
newli
synthes
compound
gener
abl
produc
signific
inhibitori
effect
activ
molecul
deriv
percentag
inhibit
fix
dose
mm
significantli
lower
prototyp
proteas
pr
inhibitor
becam
avail
proven
effect
import
mean
treat
viral
diseas
consider
research
perform
find
proteas
inhibitor
attack
viru
phase
life
cycl
led
fdaapprov
proteas
inhibitor
clinic
trail
develop
exampl
hiv
proteas
play
key
role
life
cycl
viru
inhibit
prevent
matur
viral
particl
render
noninfecti
year
discoveri
hiv
pr
remain
one
primari
target
develop
novel
hiv
treatment
recent
alloster
regul
hiv
pr
activ
recogn
novel
way
limit
develop
drugresist
xray
crystallographi
experi
show
two
indolecarboxyl
small
molecul
acid
acid
fig
could
use
fragmentlik
start
point
discoveri
novel
hiv
pr
inhibitor
although
two
fragment
show
signific
inhibit
pr
concentr
mm
addit
lucia
chiummiento
cowork
report
synthesi
antivir
activ
new
nonpeptid
heteroaromat
molecul
fig
proteas
inhibitor
among
best
one
show
moder
potenc
ic
mm
consid
novel
skeleton
eas
prepar
compound
repres
refer
structur
modif
hepat
c
viru
hcv
infect
approxim
million
peopl
worldwid
proteas
consid
one
attract
target
antihcv
therapi
essenti
viral
replic
format
infecti
viral
particl
consider
effort
differ
research
group
direct
toward
develop
hcv
proteas
inhibitor
exampl
nasser
ismail
cowork
use
comput
simul
techniqu
molecular
dock
pharmacophor
model
design
novel
indolebas
deriv
hcv
proteas
inhibitor
fig
among
compound
show
signific
high
simul
dock
score
fit
valu
compound
identifi
potent
candid
ic
valu
mm
respect
addit
nonstructur
region
hcv
genom
encod
sever
addit
enzym
believ
play
fundament
role
viral
life
cycl
rnadepend
rna
polymeras
one
central
enzym
viral
replic
cycl
emerg
especi
attract
target
drug
discoveri
effort
toward
antivir
hcv
describ
drugabl
hcv
protein
small
molecul
inhibitor
target
receiv
much
attent
recent
past
potenti
therapeut
agent
treatment
hcv
infect
includ
wellknown
antihcv
drug
sovaldi
recent
ariamala
gopalsami
cowork
design
synthes
novel
class
hcv
polymeras
inhibitor
contain
b
indol
scaffold
base
lead
compound
fig
structureact
relationship
indic
optim
aromat
region
show
prefer
pattern
scaffold
examin
favor
npropyl
moieti
posit
b
indol
scaffold
slightli
potent
correspond
exampl
b
indol
display
ic
valu
nm
nm
hcv
enzym
respect
steven
harper
cowork
report
seri
acetamid
potent
alloster
inhibitor
hcv
polymeras
enzym
fig
base
lead
structur
indolenacetamid
potent
inhibitor
enzym
show
promis
activ
replicon
assay
librarybas
approach
toward
explor
intracellular
activ
improv
establish
deriv
show
strong
potenc
cellbas
assay
routin
condit
presenc
high
concentr
human
serum
especi
compound
show
encourag
pk
properti
rat
dog
clean
extens
panel
counter
screen
assay
past
fifti
year
natur
product
serv
major
sourc
drug
fifti
percent
today
commerci
drug
deriv
natur
product
drug
avail
current
cure
viral
diseas
includ
acyclovir
model
natur
product
parent
order
discov
novel
antivir
natur
product
new
mode
action
mani
research
effort
devot
discoveri
new
antivir
natur
product
follow
focu
indol
natur
product
antivir
activ
summar
structur
properti
hope
inspir
new
even
creativ
approach
sattazolin
fig
indol
acyloin
natur
product
report
exhibit
potent
antivir
activ
id
mgml
herp
simplex
viru
type
type
drymaritin
novel
indol
alkaloid
isol
drymaria
diandra
report
exhibit
antihiv
effect
lymphocyt
ec
valu
mgml
ti
caulerpin
isol
green
alga
caulerpa
racemosa
collect
vertic
rock
wall
pedro
paulo
archipelago
report
antivir
activ
bovin
viral
diarrhea
viru
bvdv
replic
also
suggest
might
relev
evalu
antivir
activ
hcv
due
similar
characterist
minghua
chen
cowork
report
isol
seventeen
new
indol
alkaloid
fourteen
known
analogu
aqueou
extract
root
isati
indigotica
fig
compound
arvelexin
show
antivir
activ
influenza
viru
ic
valu
mm
paromita
bag
cowork
report
isol
indol
alkaloid
indol
harmalin
hm
ethnomedicin
herb
ophiorrhiza
nicobarica
demonstr
potent
activ
wild
type
clinic
isol
fig
report
indol
alkaloid
interfer
viral
immediateearli
ie
transcript
event
significantli
reduc
viru
yield
mice
welltoler
dose
ie
complex
critic
compon
herp
viru
reactiv
mechan
may
help
prevent
multipl
reactiv
hsv
provid
interest
molecular
target
develop
better
hsv
therapi
bioactiv
marin
natur
product
dragmacidin
fig
obtain
exhaust
set
protocol
marin
spong
genu
halicortex
also
report
display
modest
antivir
activ
compound
dragmacidin
f
contain
unpreced
carbon
skeleton
like
deriv
cycliz
partial
oxid
form
dragmacidin
seri
deriv
show
vitro
antivir
activ
ec
mm
ec
mm
bisindol
alkaloid
class
marin
natur
product
show
uniqu
promis
develop
new
drug
lead
fig
coscinamid
contain
unusu
function
show
partial
cytoprotect
activ
hiv
nci
assay
chondriamid
indol
enamid
show
antivir
activ
hsv
ii
ic
valu
mm
chengjian
tan
cowork
report
isol
structur
elucid
activ
three
novel
indol
alkaloid
trigonoliimin
ac
zhongli
xu
cowork
independ
report
structur
pentacycl
indolocarbazol
streptomyc
spp
fig
name
diastereom
oridamycin
xiamycin
xiamycin
b
secoderiv
indosespen
rare
endophyt
metabolit
like
play
ecolog
role
habitat
antivir
activ
may
contribut
antibiot
reservoir
mangrov
plant
jix
peng
cowork
report
isol
three
new
indol
alkaloid
three
known
alkaloid
fig
cultur
mangrovederiv
fungu
cladosporium
sp
compound
evalu
antivir
activ
influenza
viru
compound
exhibit
signific
activ
ic
mm
eudistomin
bcarbolin
deriv
fig
isol
differ
kind
ascidian
marin
tunic
famili
ascidiacea
ritterella
sigillinoid
lissoclinum
fragil
pseudodistoma
aureum
recent
investig
report
eudistomin
contain
oxathiazepin
ring
eudistomin
c
e
f
k
l
show
signific
antivir
activ
c
e
phenol
group
activ
mgdisk
eudistomin
c
e
also
report
possess
activ
rna
virus
coxsacki
viru
equin
rhinoviru
dna
virus
worth
note
indol
dimer
deriv
topsentin
bromotopsentin
fig
isol
caribbean
deepsea
spong
spongosorit
ruetzleri
exhibit
antivir
activ
corona
viru
vitro
vesivular
stomat
viru
vsv
compound
fig
isol
biolog
activ
cultur
supernat
streptomyc
sp
sihgh
et
al
cystein
proteas
inhibitor
found
nanomolar
concentr
compound
abl
inhibit
papain
hydrolyt
activ
also
show
significantli
inhibitori
activ
tumor
cell
migrat
sub
cytotox
concentr
report
macrocycl
indol
deriv
demonstr
favor
druglik
properti
includ
good
solubl
increas
lipophil
enhanc
membran
penetr
improv
metabol
stabil
good
oral
bioavail
desir
pharmacokinet
pharmacodynam
properti
compound
macrocycl
indol
deriv
current
evalu
phase
ii
clinic
trial
may
set
good
exampl
exploit
strategi
indol
macrocycl
antivir
agent
also
notic
import
class
marin
natur
product
bi
trisindol
alkaloid
show
uniqu
promis
develop
new
drug
lead
bi
trisindol
may
treat
new
drug
lead
due
uniqu
structur
function
area
well
worth
scientif
attent
wherein
lie
huge
potenti
develop
new
activ
compound
explor
variou
biolog
activ
may
use
novel
lead
structur
futur
abund
heterocycl
natur
indol
commonli
found
biolog
activ
natur
product
pharmaceut
agrochem
increas
interest
use
indol
deriv
bioactiv
molecul
differ
kind
diseas
review
updat
recent
develop
current
statu
import
indol
deriv
area
antivir
drug
discoveri
serv
comprehens
overview
indol
antivir
agent
market
clinic
trial
well
current
evalu
experiment
studi
focu
recent
develop
indol
compound
antivir
agent
promot
idea
indol
macrocycl
bi
tri
indol
novel
lead
structur
might
exploit
futur
